| Literature DB >> 22642335 |
Jeffery J Auletta1, Amelia M Bartholomew, Richard T Maziarz, Robert J Deans, Robert H Miller, Hillard M Lazarus, Jeffrey A Cohen.
Abstract
Multiple sclerosis (MS) is an inflammatory <span class="Disease">neurodegenerative disease of the CNS for which only partially effective therapies exist. Intense research defining the underlying immune pathophysiology is advancing both the understanding of MS as well as revealing potential targets for disease intervention. Mesenchymal stromal cell (MSC) therapy has the potential to modulate aberrant immune responses causing demyelination and axonal injury associated with MS, as well as to repair and restore damaged CNS tissue and cells. This article reviews the pathophysiology underlying MS, as well as providing a cutting-edge perspective into the field of MSC therapy based upon the experience of authors intrinsically involved in MS and MSC basic and translational science research.Entities:
Mesh:
Year: 2012 PMID: 22642335 PMCID: PMC3381871 DOI: 10.2217/imt.12.41
Source DB: PubMed Journal: Immunotherapy ISSN: 1750-743X Impact factor: 4.196